Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 13, 2007 Brian Lawler	Rock-Solid News From Onyx Results show that the drug Nexavar works in another type of cancer. But investors need to consider other issues when taking a closer look at this pharma.
The Motley Fool June 13, 2007 Brian Orelli	Evaluating a One-Trick Pony There is no doubt that investors should have bought Onyx Pharmaceuticals at its lows last December: The stock has tripled since then. The more important question is, what should you do now? Let's take a look at where Onyx is going.
The Motley Fool October 12, 2009 Brian Orelli	Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company.
The Motley Fool October 8, 2010 Luke Timmerman	Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening.
The Motley Fool August 27, 2007 Brian Orelli	Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.
The Motley Fool June 21, 2007 Brian Lawler	Onyx on the Clock The one-drug wonder's partner files a marketing application to expand the use of its lead drug. Investors, take note.
The Motley Fool July 26, 2010 Brian Orelli	Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug.
The Motley Fool June 28, 2007 Brian Orelli	Onyx's Hard at Work Onyx's future depends on getting Nexevar approved for new indications. The liver cancer expansion is a nice start, and it should bring Onyx into the black. Investors, take note.
The Motley Fool November 8, 2007 Brian Orelli	Investors Prefer Black Onyx Sales of Onyx's only drug, Nexavar, exceeded $100 million in the third quarter, enough for Onyx to show a profit. Investors, take note.
The Motley Fool June 5, 2007 Billy Fisher	Onyx on Fire It is readily apparent that investors in the biopharma will sink or swim on the future results of Nexavar. The ASCO meeting marks an integral win for the company, but only time will tell whether the drug can push the company into the black.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool August 8, 2007 Brian Orelli	Onyx Is Almost There Onyx Pharmaceutical narrowed losses for the quarter, and things should improve even more in the months to come, even as their bottom line is still being hampered by endless clinical trials.
Pharmaceutical Executive November 1, 2012	Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes.
The Motley Fool December 5, 2006 Brian Lawler	Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder.
The Motley Fool May 14, 2007 Brian Lawler	Onyx Rocks The oncology-focused biotech announces first-quarter financial results. Investors, take note.
The Motley Fool February 21, 2008 Brian Orelli	Onyx's Double Dose of Trouble Poor clinical trial data and a lack of profits hit the drugmaker hard. Investors, take note.
Pharmaceutical Executive November 1, 2013 Ben Comer	2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
Pharmaceutical Executive September 1, 2008	Place Your Bets The pharmaceutical industry is changing. Here are eight seminal events that describe how.
The Motley Fool November 20, 2007 Brian Orelli	Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock.
The Motley Fool May 7, 2008 Brian Orelli	Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
The Motley Fool December 12, 2011 Brian Orelli	FDA Irony: Less Data, Longer Review Poor Onyx Pharma.
The Motley Fool March 22, 2005 Charly Travers	Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials.
Pharmaceutical Executive December 1, 2005 Ron Feemster	The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool June 1, 2007 Brian Lawler	Wyeth's On a Roll The FDA approves a kidney cancer fighting compound from Wyeth. Investors, take note.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool August 6, 2008 Brian Orelli	Onyx in the Black -- for Now Positive earnings, but losses may be ahead. Will Onyx be able to keep costs under control?
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
The Motley Fool May 19, 2011 Brian Orelli	Pfizer Goes for a One-Two Blockbuster Knockout The pharma giant already has Sutent approved to treat kidney cancer, and now it's hoping to follow up that treatment with axitinib.
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
The Motley Fool October 13, 2011 Sean Williams	How to Turn Onyx Into Gold A settlement with Bayer turns Onyx into an instant buyout candidate.
The Motley Fool December 29, 2011 Brian Orelli	What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies.
The Motley Fool September 23, 2009 Brian Orelli	Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer.
The Motley Fool August 5, 2009 Brian Orelli	Potential Can't Buy Me Love It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but Onyx isn't going to get any love until it gets some positive clinical trial data.
The Motley Fool November 21, 2008 Brian Orelli	Coughing Is Bad for Amgen's Health Safety concerns halt drug trial, but all is not lost.
Chemistry World September 4, 2013 Sarah Houlton	Amgen snaps up Onyx in huge biotech deal The $10.4 billion deal gives Amgen access to the recently approved multiple myeloma drug carfilzomib (Kyprolis), plus several other partnered anticancer agents that are already on the market.
The Motley Fool January 3, 2012 Brian Orelli	High Expectations Trump Solid Results AVEO slumps despite solid results for tivozanib.
The Motley Fool June 2, 2008 Brian Orelli	Valuing One-Drug Wonders With only one drug on the market, these pharmas lack positive earnings.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
The Motley Fool December 19, 2011 Brian Orelli	ARIAD's Prolific 2011 The biotech is doing something right.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
Chemistry World April 17, 2008 Nuala Mora	World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer.
The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
The Motley Fool August 11, 2010 Brian Orelli	Amgen Comes Up a Little Short Amgen's drug Vectibix improves survival, but not by enough.